Destiny Pharma plc (“Destiny Pharma” or the “Company”) Investor Presentation Brighton, United Kingdom – 15 April 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused […]
Wednesday April 14, 2021
Audited results for the year ended 31 December 2020 and positive Phase 2b data announced...
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Audited results for the year ended 31 December 2020 Phase 2b XF-73 clinical trial: patient recruitment completed and positive Phase 2b data […]